---
title: "VK2735 in Chronic weight management: VANQUISH-2"
description: "Formulary evidence on VK2735 in Chronic weight management: VANQUISH-2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 41 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/vanquish-2"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VANQUISH-2

<a id="heading-3.1.2"></a>

## 3.1.2 VANQUISH-2

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Study objective in the design poster

> “VANQUISH-2 will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adult individuals with BMI ≥27 kg/m2 and T2D”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.1-2"></a>

#### Study objective in the ClinicalTrials.gov record

> “This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.1-3"></a>

#### Cardiometabolic hypothesis in the congress abstract

> “Capture of cardiometabolic (CM) parameters in studies with VK2735 will provide critical data to determine improvement in CM measures and may support the potential long term benefit on CVD-related outcomes.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-06-23”
> “Primary Completion (Estimated) 2027-07-01”
> “Study Completion (Estimated) 2027-08-01”
> “First Posted 2025-08-05”
> “Last Update Posted 2026-04-07”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 127 locations”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.2-3"></a>

#### Number of randomizing sites in the baseline poster

> “1013 participants were randomized from 127 U.S. study sites”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.2-4"></a>

#### Recruitment from United States sites

> “Participants will be recruited from sites in U.S. and will be randomized to receive a weekly subcutaneous injection of placebo or VK2735 (7.5-, 12.5-, or 17.5-mg).”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.2-5"></a>

#### Completion of enrollment

> “Study completed enrollment in March 2026 of 1013 adults with BMI ≥27 kg/m2 and T2D”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

> “Enrollment completed in 1Q26”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.2.2-6"></a>

#### Expected completion and timing of data

> “During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Data Expected 2H27”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The cadence of the SubQ data, we would expect the VANQUISH-1 study to read out first since that was enrolled first.”
> “Then VANQUISH-2 to read out second.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Design, duration, randomization ratio, and stratification

> “VANQUISH-2 (NCT07104383) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel arm study”
> “The duration of the study is 78 weeks, with a 6-week follow-up period”
> “Participants with type 2 diabetes and obesity or overweight will be randomized 3:2:3:3 to the study arms below and will be stratified by sex”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

> “VANQUISH-2 is a Phase 3, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy, safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese or overweight with T2DM.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.3-2"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.3-3"></a>

#### Allocation of fewer participants to the lowest dose

> “It was higher than what we'd explored in the phase II study.”
> “And they didn't have a problem with it, provided that we had more randomized to those higher dose arms than the lower dose arms.”
> “Just the low, the 7.5 is a little bit smaller than the 12.5 and the 17.5.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

<a id="topic-3.1.2.3-4"></a>

#### Diversity action plan

> “A diversity action plan (gender, race/ethnicity, age, socioeconomic status) was implemented to promote broad, inclusive participation to optimize study generalizability”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.3-5"></a>

#### Extension study after the 78-week treatment period

> “Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks.”
> “The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Each study will include an extension portion that allows participants to continue treatment after completing the primary dosing period, including patients randomized to placebo for the initial 78-week treatment period.”

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

> “The study includes a 52-week extension period allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period.”

Source: [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key inclusion and exclusion criteria in the design poster

> “Adults ≥18 years of age”
> “BMI ≥27 kg/m2”
> “Diagnosed with T2D according to the American Diabetes Association, with HbA1c ≥7% to ≤11% at screening, and on stable therapy for the last 3 months prior to screening”
> “Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes except T2D”
> “Prior or planned bariatric surgery”
> “≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemia unawareness within 6 months of screening”
> “Proliferative diabetic retinopathy, or diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment”
> “Recent significant weight changes (≥5% within 3 months of screening)”
> “History of acute or chronic pancreatitis”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.4-2"></a>

#### Key criteria in the congress abstract

> “Key inclusion criteria are adults with BMI ≥27 kg/m2. Key exclusion criteria are current or past diagnosis of type 1 DM, severe hypertriglyceridemia, prior or planned surgical tx or endoscopic and/or device-based tx for obesity and eGFR <30mL/min/1.73m2.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.4-3"></a>

#### Inclusion criteria and permitted background glucose-lowering therapy in the ClinicalTrials.gov record

> “Age ≥18 years of age at the time of signing the informed consent”
> “Body mass index (BMI) ≥27 kg/m2”
> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.4-4"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)”
> “Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening”
> “Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.5-2"></a>

#### Subcutaneous formulation: dose arms, time at target dose, and lifestyle counseling

> “Participants will be recruited from sites in U.S. and will be randomized to receive a weekly subcutaneous injection of placebo or VK2735 (7.5-, 12.5-, or 17.5-mg). The tx period at the final target dose for each group will be a minimum of 52 weeks. Participants will receive lifestyle counseling throughout the tx period and should participate in ≥150 of physical activity per week in addition to a balanced, hypocaloric diet.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

> “Matched placebo”
> “7.5 mg weekly SC VK2735”
> “12.5 mg weekly SC VK2735”
> “17.5 mg weekly SC VK2735”
> “All groups: Counseling for reduced calorie diet and exercise”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.5-3"></a>

#### Subcutaneous formulation: dose titration from 1.25 mg

> “So four arms, placebo, 7.5, 12.5, and 17.5. All of these will go with a 2.5 mg uptick in titration, but they will all also start at 1.25 mg. So two weeks at 1.25 and then four weeks at 2.5, four weeks at 5, and so on up to 17.5. And when you get to 17.5, that's when the 52-week stable dose window starts.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

> “Which is one of the reasons we started at 1.25 mgs in the VANQUISH studies.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.2.5-4"></a>

#### Subcutaneous formulation: transition from vial and syringe to autoinjector

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735.”
> “We are happy to report that this study was successfully completed, enabling the introduction of the autoinjector for all participants in the VANQUISH program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “In the Q1 of 2026, participants in both VANQUISH studies began transitioning to the auto-injector device.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

> “I think for VANQUISH 2, almost everybody is on the auto-injector.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint

> “Percent change in body weight from baseline to Week 78 in body weight”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

> “The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment.”

Source: [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)

<a id="topic-3.1.2.6.1-2"></a>

##### Secondary endpoint: categorical weight reduction

> “Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.6.1-3"></a>

##### Glycemic and cardiometabolic outcomes and adjudicated safety events

> “Assessed changes in T2DM and CM-related parameters will include HbA1c, BMI, waist circumference, blood pressure and lipid profile. Safety and tolerability will also be assessed. Pancreatitis, gallbladder and CV events will be adjudicated.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.6.1-4"></a>

##### Additional outcomes: function, cardiometabolic health, mental health, and work productivity

> “Physical functioning (SF-36 v2, IWQoL)”
> “hsCRP, MACE, ALT, AST, eGFR”
> “Work Productivity & Activity Impairment”
> “Measures that influence treatment adherence and persistence will also be collected (e.g., health-related quality of life, physical and mental well-being, work productivity, and treatment satisfaction)”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.6.1-5"></a>

##### Rationale stated in the design poster and the baseline poster

> “For people living with obesity and T2D, weight reduction is now recommended as a key element of diabetes treatment, since it can improve glycemic control and decrease cardiometabolic risk factors, while greater body weight reduction (≥10%) has been reported to lead to remission of diabetes”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

> “Clinical guidelines (e.g., ADA, AACE) recommend achieving and maintaining weight reduction (e.g., >10%) as a primary therapeutic goal in adults with obesity and T2D to improve obesity-related complications”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.6.1-6"></a>

##### Regulatory basis for the primary endpoint and for glycemic secondary endpoints

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “control group.”
> “A1C (in subjects with type 2 diabetes)”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment

> “Approximately 1,122 participants will be randomized in the study”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

> “The VANQUISH-2 study will target enrollment of approximately 1100 adults with type 2 diabetes who are obese or overweight.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="topic-3.1.2.7.1-2"></a>

##### Planned participants per arm in the design poster

| Arm | Planned participants |
| --- | --- |
| Placebo | “n=306” |
| VK2735 7.5 mg | “n=204” |
| VK2735 12.5 mg | “n=306” |
| VK2735 17.5 mg | “n=306” |

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.7.1-3"></a>

##### Randomized participants per arm in the baseline poster

| Arm | Randomized participants |
| --- | --- |
| Placebo | “N=276” |
| VK2735 7.5 mg | “N=185” |
| VK2735 12.5 mg | “N=276” |
| VK2735 17.5 mg | “N=276” |
| Total | “1013 participants were randomized from 127 U.S. study sites” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.7.1-4"></a>

##### Enrollment reported after completion

> “The trial enrolled approximately 1,000 adults with type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2).”

Source: [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)

> “The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Population analyzed for baseline characteristics

> “Analyze preliminary baseline demographic data from the randomized population of the VANQUISH-2 study”
> “The VANQUISH-2 eligibility criteria (age ≥18, BMI ≥27, physician-diagnosed diabetes) were applied to the 2021-2023 NHANES data set”
> “These data are based on surveys from 607 people who met VANQUISH-2 inclusion criteria; 584 with positive phlebotomy weight”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.7.2-2"></a>

##### Efficacy and safety analysis sets

No evidence found.

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Randomized participants

> “1013 participants were randomized from 127 U.S. study sites”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.1-2"></a>

##### Blinded discontinuation rate across the VANQUISH program

> “The discontinuation rate is tracking our expectations. It's blinded data, so it's really difficult to interpret why someone discontinues. But the overall rate is within what we expected when we designed the study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographics and body size compared with NHANES

| Characteristic | VANQUISH-2 (N=1013) | NHANES |
| --- | --- | --- |
| Age, mean (SD), years | “58.3 (11.5)” | “59.51 (11.7)” |
| Age 65 years or older | “31%” | “38%” |
| Sex, female to male, % | “49:51” | “49:51” |
| Weight, mean (SD), kg | “105.3 (23.5)” | “99.8 (20.2)” |
| Waist circumference, mean (SD), cm | “118.2 (15.8)” | “116.4 (12.6)” |
| BMI, mean (SD), kg/m2 | “37.1 (7.1)” | “35.7 (6.2)” |
| BMI 27 to less than 30 kg/m2 | “13%” | “22%” |
| BMI 30 to less than 35 kg/m2 | “32%” | “34%” |
| BMI 35 to less than 40 kg/m2 | “26%” | “22%” |
| BMI 40 kg/m2 or higher | “29%” | “22%” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-2"></a>

##### Age distribution compared with NHANES

| Age group, years | VANQUISH-2 (N=1013) | NHANES |
| --- | --- | --- |
| 18 to 34 | “3%” | “5%” |
| 35 to 44 | “11%” | “8%” |
| 45 to 54 | “22%” | “16%” |
| 55 to 64 | “34%” | “33%” |
| 65 to 74 | “25%” | “26%” |
| 75 or older | “6%” | “12%” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-3"></a>

##### Race and ethnicity, prior GLP-1 receptor agonist exposure, and diabetes duration

| Characteristic | VANQUISH-2 (N=1013) |
| --- | --- |
| Non-Hispanic White | “43%” |
| Hispanic or Latino | “29%” |
| Non-Hispanic Black | “20%” |
| Non-Hispanic Asian | “4%” |
| Other | “3%” |
| Prior exposure to a GLP-1 receptor agonist | “21%” |
| Time since type 2 diabetes diagnosis, mean (SD), years | “10.3 (8.1)” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

> “NHANES race distribution: 57% Non-Hispanic White, 16% Non-Hispanic Black, 8% Other.”
> “GLP-1, GLP1/GIP, GLP-1/GLP/Glucagon receptor, CagriSema, or Amycretin used prior to enrolling in this study.”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-4"></a>

##### Baseline obesity complications compared with NHANES

| Complication | VANQUISH-2 (N=1013) | NHANES |
| --- | --- | --- |
| Hypertension | “67%” | “79%” |
| Dyslipidemia | “66%” | “89%” |
| Sleep apnea | “25%” | “NHANES comparator not available for sleep apnea.” |
| Osteoarthritis | “22%” | “31%” |
| Asthma | “11%” | “16%” |
| Coronary artery disease | “8%” | “17%” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-5"></a>

##### Representativeness stated by the authors

> “Mean age and gender were comparable between VANQUISH-2 and NHANES”
> “Mean BMI, weight, and waist circumference were modestly higher in VANQUISH-2”
> “Prevalence of obesity complications was lower in VANQUISH-2 than the NHANES population”
> “Laboratory parameters were generally consistent with those expected in this patient population”
> “These preliminary baseline data indicate the VANQUISH-2 randomized population is largely representative of the adult U.S. population with BMI ≥27 kg/m2 and T2D”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

> “These baseline data indicate the VANQUISH-2 randomized population is representative of the adult U.S. population with BMI ≥ 27 kg/m2 and Type 2 diabetes.”

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: limitations evident from the available VANQUISH-2 documents

VANQUISH-2 is ongoing, with primary completion estimated for July 2027, data expected in the second half of 2027, and readout expected after VANQUISH-1, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, a congress abstract and poster authored by company employees, and a baseline poster authored by company employees and study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Enrollment fell short of the plan: the design poster planned approximately 1,122 participants (306 per arm and 204 in the 7.5 mg arm) and the initiation release targeted approximately 1100, while 1,013 participants were randomized (276 per arm and 185 in the 7.5 mg arm).

The 7.5 mg arm is the smallest, so estimates for that dose will be less precise. The trial enrolled adults with type 2 diabetes and HbA1c of 7% to 11% in the United States and Puerto Rico only; background therapy with DPP-4 inhibitors, amylin analogues, GLP-1 receptor agonists, and dual GLP-1/GIP receptor agonists was not permitted, while 21% of participants reported prior GLP-1 receptor agonist exposure. Participants had a mean BMI of 37.1 kg/m2 and a mean diabetes duration of 10.3 years, and the prevalence of obesity complications was lower than in the NHANES comparison population. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector, and in July 2026 the company stated that “almost everybody” in VANQUISH-2 was using the autoinjector. The extension study is expected to report in 2028 and will not inform the primary 78-week analysis.

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383); [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf); [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/); [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
